Member Info for allah4uk

DEFO A SINGLE PERSON CAN ACHIEVE NOT SO INCONSEQUENTIAL SALES, IF THE RIGHT DEALS CAN BE STRUCK.

THAT BEING SAID, FOR BETTER, WIDER MARKET PENETRATION - I GUESS A SPECIALISED, IN-HOUSE SALES TEAM WOULD BE NECESSARY TO PROPERLY TAP INTO DAT MARKET.

CHRIS, BRUV, IT'S ALWAYS GOOD TO DOUBT.

THE PROBLEM IS WHEN YOU LET THE DOUBTS LINGER IN THE FACE OF OVERWHELMING POSITIVE EVIDENCE.

FACT - NOVACYT HAS BEEN RAKING IN CASH SINCE JANUARY.

FACT - NOVACYT HAS BEEN USING ITS CASH VERY WISELY.

FACT - THANKS TO THE ABOVE, NOVACYT HAS LANDED A MEGA CONTRACT.

FACT - SAID MEGA CONTRACT PROVIDES GOOD VISIBILTY TO THE COMPANY.

WHAT MORE COULD ONE WANT ?
THIS COMPANY HAS BEEN SAVED FROM BANKRUPTCY, AND THERE'S NO TURNING BACK.

YOU POINTED IT YOURSELF.

WHAT MAKES YOU DOUBT, STILL, IS THE OTHER INVESTORS' BEHAVIOUR.

WELL, IT'S PRETTY SIMPLE : NEVER FORGET THAT THE MARKET IS OFTEN IRRATIONAL.

IF PEOPLE SELL TOO EARLY - IT'S THEIR LOSS (IN MISSED PROFITS).
IN THE STOCK MARKETS, ONE OF THE MOST VALUABLE SKILL THAT ONE CAN DEVELOP IS : PATIENCE.

GOOD INTUITION EXMEX, A LOT MIIGHT HINGE ON THE QMUL TRIAL'S REPORT.

IT MIGHT UNLOCK THE SECOND PHASE OF THE CONTRACT AND ALSO OPEN MORE CARE HOMES DOORS. NOT TO MENTION THE OPPORTUNITIES ABROAD, WITH NOVACYT SALES TEAM PITCHING THE "SCIENTIFICALLY PROVEN" ADVANTAGE OF CONDUCTING REGULAR, HIGHLY ACCURATE PCR TESTS IN AT-RISK SETTINGS.

NO FIGURES ON STOCKS WERE GIVEN (OBV.) BUT THE LAST RNS, IIRC, DID STRESS THAT INCREASED PRODUCTION WAS UNDERWAY. SO CERTAINLY NCYT ANTICIPATES THAT THEIR INSTRUMENTS SALES WILL TAKE OFF - AND NOT ONLY FOR THE GIANT NHS ORDERS, I SURMISE.

WHAT I ANTICIPATE THE MOST, AND HASN'T BEEN REITERATED TODAY, IS THE REDUCTION IN TESTING TIME : SUPPOSEDLY "SIGNIFICANTLY LESS THAN 60 MINUTES".
IT MUST BE A FURTHER REFINEMENT OF EXSIG DIRECT, SINCE THE LATTER DID PERMIT A TIME REDUCTION FROM 90 MINS TO 60 MINS, BUT NO MORE.

GOOD ARTICLE FROM THE TORYGRAPH : HTTPS://WWW.TELEGRAPH.CO.UK/NEWS/2020/09/28/TESTING-CARE-HOME-STAFF-RESIDENTS-REMAINS-UNRESOLVED-FIASCO/

MOST NOTABLY THE FOLLOWING QUOTES :

"PROFESSOR MARTIN GREEN, THE CHIEF EXECUTIVE OF CARE ENGLAND, SAID THE PROBLEM WITH TESTING IN CARE HOMES "IS GETTING WORSE, NOT BETTER" BECAUSE "TEST RESULTS ARE NOT COMING BACK QUICKLY ENOUGH""

" IF YOU WANT TO KEEP CARE HOMES FREE OF CORONAVIRUS THEN THEY NEED THEIR TEST RESULTS BACK IN MINUTES, NOT DAYS."

MINUTES YOU SAID ? BODES WELL FOR US SINCE WE CAN PROVIDE EXACTLY THAT !
TESTING WITH THE Q32 AND OPTIMISED TEST TAKES LESS THAN 60 MINUTES.

HOPEFULLY THE NPT TEST RESULTS WILL BE RELEASED IN A FEW WEEKS.

YOU GO GUY !

AVACTA OFFERS A FORMIDABLE POTENTIAL... ON PAPER. THE ISSUE IS THAT THEY HAVE YET TO RELEASE THEIR FAMOUS QUICK TEST, LET ALONE SELL A SINGLE UNIT.
NOT SAYIN IT WON'T HAPPEN. BUT WHO KNOWS WHEN ? AND UNDER WHICH CONDITIONS ? WILL THE MANAGEMENT DELIVER EXACTLY WHAT IT PROMISED ??

ON THE OTHER HAND, WHEN BUYING NCYT YOU'RE BUYING THE MANAGEMENT ABOVE ALL. YOU'RE BUYING QUALITY LEADERSHIP, FROM WHICH QUALITY PRODUCTS ARE DELIVERED IN A TIMELY MANNER.
THE SP WILL HAVE ITS UPS AND DOWNS, BUT MORE OFTEN THAN NOT IT WILL *NOT* REFLECT THE INTRISINCT QUALITY OF THE SHARE.

TOO MANY RNS THREADS AS USUAL, MIGHT AS WELL CREATE MINE TO CENTRALISE TALKS ABOUT NUMBERS.

SO IF I READ IT RIGHT, THE 1ST PHASE OF THE NHS CONTRACT IS WORTH UP TO *250 MILLIONS*.
AND THEN IN A 2D PHASE, THAT AMOUNT COULD BE EVEN "MARKEDLY HIGHER" THAN THE 1ST PHASE.

I'M NOT EVEN SURE I READ THAT RIGHT. IT BOGGLES THE MIND. BUT THEN AGAIN, THRDR DIZZYING FIGURES WOULD BE COMPLIANT WITH THE "MOONSHOT3 PROJECT.

JUST ROFLMAO @ THAT GUY ! HE COULD DE-RAMP ON GDR WHERE THE DEVASTATED PSYCHOLOGICAL TERRAIN IS PERFECT FOR THAT... BUT OF ALL BOARDS HE CHOSE NCYT :DDDDD

MDR @ YOU INADEQUATE TROLL

RE THE TESTING TIME : "SIGNIFICANTLY BELOW 60 MINUTES" AS PER THE INTERIM RESULTS RNS.

RE VERSALAB/PROMETA : ONE OF THESE SHOULD BE THE ANTIBODY TEST'S COMMERCIAL NAME.

IF WHAT TAYLOR IS SAYIN' BE RITE : https://twitter.com/TaylorQuant/status/1310692417872461830

THEN I CAN BARELY CONTAIN MY ECSTASY !

ACTUALLY THE 2020'S AG RESOLUTION ARE PRETTY MUCH COPY-PASTED FROM LAST YEAR'S AG : https://novacyt.com/wp-content/uploads/2019/05/NVT-SOC-AGM-resolutions-ENG.pdf

EXCEPT THIS TIME THE SP SHOULDN'T DEFLATE BY HALF - HOPEFULLY.
THERE'S MUCH MORE SOLID SALES TO SUPPORT THE INCREASE IN SP.

SORRY DEAS, I HAD WHAT BLADESHARP QUOTED IN MIND.

E.G. PRICE PER UNIT OF THE REGULAR CORONA TEST : 8£ => MORE LIKE 4£.
SAME GOES FOR INSTRUMENTS. A Q32 SOLD IN BULK WON'T GO FOR 20K£.

IT SAYS 300 - STILL A GREAT ORDER ZO.

NOTE TO DEAS : I THINK THE CALCULATIONS YOU LAID OUT ON TWATTER ARE A BIT TOO OPTIMISTIC. THINK *BULK* PRICES AND CUT YOUR PER UNIT FIGURES BY HALF.

ODDO IS A FAMILIAR NAME OVER THE POND, CERTAINLY A RESPECTABLE BANK.

BESIDES PROVIDING A BROKER'S ASSESSMENT (WITH TARGET SP), THEY COULD CERTAINLY HELP BRING IN ADDITIONAL INVESTMENT (REMEMBER THEY'RE PRIVATE BANK TOO) AND ADVICE REGARDING A POTENTIAL BUSINESS EXPANSION ON THE CONTINENT.

For sure Saint, not the type to ramp things up - that's why he's worthy of being heeded !

As for me, I'm off already, and will have to follow the news by proxy : if the mongos on Bourso start cheering and the SP is rising, I'll know that some legit news will have beefed up the share.

Here's hoping that we'll have a good day lads.

Thanks for chiming in Blade - so I'm guessing you've uncovered some pretty clue regarding the upcoming antibody test... and hopefully it'll validate the speculation regarding who dat "big" partner is ??

It looks like our bruv Bladesharp might finally unveil the mysterious sales numbers he told us about : https://twitter.com/Blad3sharp/status/1308524786734321664

"Early" isn't well defined, but 8am seems the upper limit to me.

Exactly, Novacyt has seriously raised its profile of late, but only hard numbers can definitely propel the SP.

Now, to be faire to GM, I don't think he intentionally tried to hide the individual companies' performance.

The Interim Report did specifically state that Microgene's activity was negatively impacted by the conjoncture (which, in turn, dramatically stenghtened Primerdesign's sales).
No figures were given, but the state of affairs is pretty explicit.

Also the breakdown of revenue will be specified in the Annual Report, as has happened in the previous years. So the information will be provided - albeit at a later date.